Reviewed 27 October 2026. Scope: Japan, with a U.S. comparison. Statistical dates are stated below.
Not automatically. A private clinic’s license, a filed treatment plan, or a registered trial is not government endorsement of the treatment’s effectiveness. Some specific cell therapy products do have regulatory approval for defined uses. In Japan, filing a plan under the Act on the Safety of Regenerative Medicine is different from obtaining product marketing approval from the Ministry of Health, Labour and Welfare (MHLW) following review by the Pharmaceuticals and Medical Devices Agency (PMDA). Neither status guarantees an individual patient’s outcome. Plan000280868.pdf

If a clinic says its treatment is “government-approved,” ask what was approved, by which authority, and for which use. A clinic license, a treatment-plan listing, a product approval, and permission to conduct research answer different questions. Private ownership or self-pay billing does not tell you which regulatory status applies.
Japan’s filings and approvals
MHLW’s report dated 30 June 2026 records 6,743 treatment plans: 8 Class I, 2,463 Class II, and 4,272 Class III. It separately records 85 research plans. These are plan counts, not patient numbers, unique clinics, or proven treatments. Risk classes determine regulatory procedures; they are not rankings of effectiveness. 001590173.pdf
PMDA’s 20 May 2026 presentation reports 26 approved regenerative medical products after excluding two withdrawn or expired approvals. This category includes gene therapies as well as cell- and tissue-based products; it is not a count of generic stem cell treatments available at private clinics. The plan and product totals describe different units, legal routes, and dates. They cannot be used to calculate an approval rate or a patient’s chance of benefit. 000280868.pdf
What the paperwork means
The distinction matters when reading a brochure or consent form. MHLW publishes provider and treatment information, committee names, consent-document forms, and relevant orders. Finding a clinic in those records establishes a listing, not an efficacy finding. 0000186471
| Document or claim | What to verify | What it does not establish |
|---|---|---|
| Clinic or physician license | Which institution or professional holds the license. | Approval of every treatment offered there. |
| MHLW-filed provision plan | The provider, treatment, risk class, reviewing committee, and consent documents. | Product marketing approval or proof that the treatment works. |
| Certified committee review | The committee responsible for reviewing the plan under the Safety Act. | A government recommendation to choose that clinic or procedure. |
| Product marketing approval | The named product, approved indication, eligible population, administration, and conditions. | Approval of another preparation, another disease, or the clinic’s full menu. |
| Trial registration | The study identity, protocol details, status, and any posted results. | Successful results, marketing approval, or a quality guarantee. |
| Insurance coverage | The applicable coverage and billing rules for the proposed care. | That every treatment at the clinic is covered or suitable for you. |
Under Japan’s Safety Act, providers must follow the applicable risk-based procedures, including committee review, plan submission, and reporting duties. Filing is one requirement, not blanket permission regardless of other rules. The Act also has exclusions, including certain uses of already-approved products; not every cell-based medical procedure follows the same filing route. Plan
What product approval covers
Regulatory approval is a defined legal decision, not a general recommendation for private cell therapy. Check the exact product and label rather than the word “stem cells.” The cell source, processing, dose, route, disease, and patient population all matter. Japan’s product-approval framework is separate from its provision-plan framework. 000280868.pdf
For a concrete U.S. example, the FDA approved Ryoncil (remestemcel-L-rknd) on 18 December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. It is a donor bone marrow-derived mesenchymal stromal cell (MSC) therapy administered intravenously. This disease can occur after an allogeneic blood stem cell transplant; “steroid-refractory” means it has not responded to steroid treatment. The approval does not cover a clinic’s different MSC preparation for chronic pain or anti-aging. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
The FDA announcement describes a multicenter, single-arm study of 54 pediatric participants with that disease after allogeneic transplantation. The primary effectiveness assessment concerned response at day 28 and its duration; 16 participants (30%) had a complete response and 22 (41%) a partial response at day 28. There was no concurrent comparison group. Reported common adverse reactions included infections, fever, hemorrhage, edema, abdominal pain, and hypertension. Those findings concern this product and population, not a success rate for other cell treatments or a measure of long-term cure. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
Approval status can also change. PMDA’s May 2026 timeline marks HeartSheet’s approval as withdrawn on 25 July 2024. A historical approval date alone therefore cannot establish current authorization. Japan also has conditional, time-limited approvals: the framework allows a period of up to seven years, with an extension of up to three years under specified statutory conditions, and requires further data and review. That extension is not automatic, and conditional approval should not be described as unrestricted confirmation of efficacy. 000280868.pdf
Why a listing is no safety guarantee
On 13 March 2026, MHLW ordered a temporary suspension involving a Tokyo clinic’s autologous adipose-derived MSC plan for chronic pain after a foreign patient deteriorated during administration and was later confirmed dead. The cause had not been established when the order was issued. The ministry also ordered a temporary manufacturing suspension at the Kyoto processing facility identified in the notice. Newpage_71555
On 21 April 2026, MHLW issued an emergency order concerning a Fukuoka clinic. At least five people treated under its chronic-pain plan in May 2023 had developed chills, fever, nausea, or other symptoms; at least one later required inpatient care. The notice described missing required reports and cause investigation, and continued provision of treatment. These are findings about specific plans and providers, not proof that every MSC treatment is unsafe. Newpage_72690
Risks depend on the product and procedure. The FDA has reported infections, unwanted immune or inflammatory responses, abnormal tissue growth, and other serious harms with unapproved regenerative products. Using your own cells does not remove processing or administration risks. The Ryoncil approval announcement also identifies infusion reactions, infection-related risks, and ectopic tissue formation as possible complications of that approved product. Important patient and consumer information about regenerative medicine therapiesFda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
Trials are research, not endorsement
A clinical trial tests an intervention; a registry record describes the study. Registration is not a result, an efficacy judgment, or product approval. The FDA specifically warns that inclusion in ClinicalTrials.gov, or a firm’s registration with the FDA, does not mean a regenerative product is legally marketed. A paper or testimonial likewise cannot establish approval for a different product or use. Important patient and consumer information about regenerative medicine therapies
Use Japan’s jRCT or the U.S. National Library of Medicine’s ClinicalTrials.gov to locate the study number supplied by a clinic. En topClinicaltrials.gov Ask for the protocol, ethics review, recruitment status, eligibility, cell preparation, route, study phase where applicable, enrollment, comparison group, endpoints, follow-up, adverse events, and any results. Separate what is planned from what has actually been reported. Even posted results are not themselves a marketing authorization.
A worked paperwork check
Consider a hypothetical offer of your own fat-derived cells for chronic pain. If the clinic presents an MHLW provision-plan listing, match the clinic, treatment, and consent documents. That checks the listing; it does not turn the procedure into an approved commercial product. MHLW’s provider-information page tells patients to confirm the provider and treatment names and obtain a sufficient explanation from the physician. 0000186471
If the clinic instead points to Ryoncil’s FDA approval, compare the offer with the actual approval: donor bone marrow-derived cells for a specific pediatric transplant complication are not your own fat-derived cells for chronic pain. The cell source, disease, and patient population do not match. This is a document-comparison exercise, not a patient case, a report of treatment experience, or an assessment of your eligibility. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
Check before you pay
- Identify the claim. Ask whether “approved” refers to the clinic, the plan, a named product, or a study. Request the authority’s name and the relevant public document.
- Match the Japanese record. Start at MHLW’s provider-information page and compare the clinic name, address, treatment, committee, consent forms, and any orders. Copy the Japanese name from the document if an English search is inconclusive. 0000186471
- Resolve document differences. Compare the proposed treatment with the published plan and consent materials. Ask for an understandable translation and a written explanation of discrepancies; do not assume the brochure or the Japanese form is automatically sufficient. When reviewing registration and compliance in Japan, keep plan filing separate from product approval.
- Identify the preparation. Obtain the cell source, processing facility, dose, route, and treatment schedule. These details should identify what you will actually receive during the treatment process in Japan, not just a broad cell type.
- Check the claimed approval. Obtain the current product label and any approval conditions. Match the indication and population to your diagnosis. For a trial, distinguish registration, oversight, and published results.
- Ask for evidence and alternatives. Request the number of comparable patients studied, trial design, measured benefits, duration of follow-up, serious adverse events, and the standard care that could be delayed or replaced. These are also useful questions when choosing a stem cell hospital in Japan.
- Set out the costs and aftercare. Request the full written cost, insurance status, follow-up schedule, complication plan, and the physician responsible. A grant, partnership, or payment arrangement cannot substitute for a product’s approval record.
Be wary of an approval for another disease, a plan described as proof of benefit, an unexplained success rate, or claims of “no side effects.” If you suspect misleading medical advertising in Japan, the Medical Institution Internet Patrol provides a reporting route. Iryoukoukoku patrol.mhlw.go.jp
Before traveling to Japan
Confirm the responsible clinic and physician before booking travel. Request consent information in a language you understand, and arrange who will manage complications after you return home. Questions about screening, minimum stay, and follow-up belong in your medical travel planning for treatment in Japan; none is answered by the phrase “government-approved.” Do not delay emergency care or stop prescribed treatment while checking a clinic’s claims.
Need to clarify the proposed treatment?
Contact the clinic to ask which treatment and documents apply to your inquiry. The clinic’s response does not replace verification with the regulator or advice from your own physician.
The answer to the claim
Private cell therapy is not government-endorsed simply because a clinic offers it legally or appears in a public register. A specific product may be approved for a specific use, but that does not approve the clinic’s other procedures or guarantee benefit. Ask for the exact document, check what it authorizes, and compare it with the treatment you are being offered.
A plan filing, a product approval, and evidence that a treatment is right for you are three different things.
Sources and limits
This is a regulatory explainer, not a clinic audit, a clinical review of every cell therapy, or individual medical or legal advice. The worked example is hypothetical; no patient experience or clinical credentials are claimed. Japanese filing statistics are dated 30 June 2026; PMDA’s product figures are dated 20 May 2026. These are dated snapshots, not a current approval count for every jurisdiction. Sources were reviewed on 27 October 2026. Verify the current product label, plan, and any restrictions before deciding. Internal links are the clinic’s own information pages, not independent evidence of safety or effectiveness.




